RBM10 and familial pancreatic carcinoma: The CCK-8 assay showed a significant increase, approximately 1.5 times, in the viability of PATU-8988 and PANC-1 cells following RBM10 knockdown, suggesting successful knockdown and promotion of pancreatic cancer cell proliferation (P < 0.05) (Fig. 2E).